The Role of Myeloid-Derived Suppressor Cells in Lung Cancer and Targeted Immunotherapies Publisher Pubmed



Sheida F^{1, 2} ; Razi S^{1, 3, 4} ; Keshavarzfathi M^{1, 4, 5} ; Rezaei N^{4, 6, 7} Show Affiliations
Source: Expert Review of Anticancer Therapy Published:2022

Abstract

Introduction: Lung cancer is the deadliest cancer in both sexes combined globally due to significant delays in diagnosis and poor survival. Despite advances in the treatment of lung cancer, the overall outcomes remain poor and traditional chemotherapy fails to provide long-term benefits for many patients. Therefore, new treatment strategies are needed to increase overall survival. Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells taking part in lung cancer, as has been described in other types of tumors. MDSCs immunosuppressive activity is mediated by arginases (ARG-1 and ARG–2), nitric oxide (NO), reactive oxygen species (ROS), peroxynitrite, PD-1/PD-L1 axis, and different cytokines. MDSCs can be a target for lung cancer immunotherapy by inducing their differentiation into mature myeloid cells, elimination, attenuation of their function, and inhibition of their accumulation. Areas covered: In this review, the immunosuppressive function of MDSCs, their role in lung cancer, and strategies to target them, which could result in increased efficacy of immunotherapy in patients with lung cancer, are discussed. Expert opinion: Identification of important mechanisms and upstream pathways involved in MDSCs functions paves the way for further preclinical and clinical lung cancer research, which could lead to the development of novel therapeutic approaches. © 2021 Informa UK Limited, trading as Taylor & Francis Group.